Introduction
With the advent of modern neuroimaging technologies in the early 1990s, the proliferation of neuroimaging devices in neurological research centers around the world has made it possible for many centers to conduct leading edge brain research in many clinical syndromes [1] [2] [3] . However, it has also become recognized that investigators from across centers can pool efforts, resources, and data toward large-scale research collaborative programs aimed at refining understanding of frequently heterogeneous diseases of brain structure and function. Studies that could not be conducted in any one site, because of lack of patient numbers or given expertise, become possible in such collaborative efforts. Archives of raw and processed datasets may be examined jointly by investigators at federated centers or by unaffiliated researchers. With access to the large-scale research outcomes, clinicians can utilize this new information to direct patient treatment plans.
Multicenter collaborations, however, require careful coordination and division of labor, compliance with Health Insurance Portability and Protection Act (HIPAA) regulations on data anonymization, and so on. Additional considerations involve how differences in scanner make, model, manufacturer, field strength, field homogeneities, slew rates, and image reconstruction routines can influence the data and potentially lead to conflicting results. Computational resources are also important for how to maximize throughput toward results that can be put directly into clinical practice. In this overview, we discuss several such multicenter efforts, note key clinical and research outcomes, and comment on the importance of careful coordination of such programs. Lastly, we discuss the potential that lies in large-scale archives of these data, and how potentially they may be mined to identify unanticipated outcomes worthy of additional collaborative effort.
Rising frequency of multisite trials
Although an increasing number of individual research centers now enjoy the latest in neuroimaging technology in the form of PET and high-field MRI, researchers have been quick to recognize the importance of pooling effort and resources toward clinically relevant goals that could not be achieved at one center alone. The numbers of established multisite clinical trials, collaborations, and research consortia has dramatically increased since the first studies using modern imaging methods first appeared (Fig. 1 ). These efforts seek to leverage complementary approaches toward mapping brain function and structure and relating these to genomic influences, psychopharmacological interventions, and treatment outcomes.
Advantages of multisite trials and collaborations
Despite the fact that many neuroimaging centers may be well equipped to carry out focused studies individually, the greatest benefit in multicenter efforts is the ability to, in principle, obtain more neuroimaging data per unit time across a wider variety of the patient population in question. This provides a great number of clinical exemplars, although also attempting to at once control issues of selectivity of patients while being able to more precisely examine patients having varying cause. In the sense of greater data acquisition, an analogy exists with parallel computing in which with multiple central processing units (CPUs) it is possible to increase throughput manifold in the same amount of time. Other major advantages of multisite neuroimaging trials include: as a tool for cognitive neuroscience research into patterns of normal and altered brain function; for prediction of which normal or slightly impaired individuals will develop alterations in brain anatomy and over what time period; for early identification of neurological disease in at-risk individuals (e.g. test sensitivity) and separation of certain forms of disease from others (e.g. disease specificity); for monitoring the progression of disease across a geographically, culturally, and environmentally diverse population; and for monitoring response to interventions and therapies. Functional imaging methods [functional MRI (fMRI), PET, and single photon emission computed tomography (SPECT)] have tended to be best suited toward tracking symptomatic therapy response, whereas anatomic imaging (structural MRI and diffusion tensor imaging) and amyloid PET [4] tend to be best suited toward disease modulation studies [5 ] . The additional potential for human neuroimaging with respect to pharmacological intervention or candidate gene studies is enormous [6] . By taking advantage of a wider variety of patient types, causes, and range of symptoms, multisite studies can be better representative of the larger patient population with greater generality for population-level atlases of brain structure/function and, by their association with clinical variables, suggest treatment options with the widest possible efficacy. For the clinician, this translates into the greater ability to consider treatment options for Exploration of PubMed citations, grouped into 3-year periods, reveals consistent increases in the numbers of publications concerning multicenter efforts since the early 1990s. Examples of several leading multicenter programs are listed in Table 1 .
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patients against a number of demographic, case history, and etiological backgrounds.
Challenges in multisite trial coordination
Although being geographically distributed is, from a patient demographics point of view, a principal strength of multicenter efforts, a number of challenges exist in coordinating such programs. These include issues concerning variation in scanner technologies across centers in which even the same make and model of MRI system may demonstrate differing field inhomogeneity effects that can influence how data might be interpreted [7] . Even subtle distortions in scanner magnetic field homogeneity across sites can form an unwanted source of variance that must be controlled through the use of standardized phantom studies [8] and strict quality assurance of imaging protocols. Trial considerations also involve patient confidentiality and how investigators can have access to patient data and private health information stored at other institutes while also being compliant with HIPAA privacy regulations [9] . At the same time, methods for ensuring seamless computational access for researchers to digital archives of neuroimaging and clinical data for use in comparative analysis and modeling necessitate careful examination. The factors include: site-to-site networking requirements [10] ; user authentication protocols [11] ; means for rapid design and deployment of analysis workflows [12] ; data ontological definition, description, and data management [13] ; and large-scale data storage capabilities [14 ] . Regularly scheduled 'all-hands' meetings supplemented with conference calls and web-meetings are necessary for measuring progress toward the stated aims of the trial. Multicenter trials, especially involving neuroimaging, are expensive, involving multiple investigators, imaging center hourly rates for scanning, travel, and other associated costs. Despite these challenges, the recent increase in the numbers of such multisite trials and collaborations is indicative that policy makers and funding organizations recognize their benefits and understand them to be a worthy scientific, clinical, and financial investment. 
Successful examples in multisite neuroimaging

Alzheimer's disease neuroimaging initiative
The pathophysiologic process leading to neurodegeneration in Alzheimer's disease is thought to begin long before clinical symptoms develop. Existing therapeutics for Alzheimer's disease improve symptoms, but increasing efforts are being directed toward the development of therapies to impede the pathologic progression of the disease. Although these medications must ultimately demonstrate efficacy in slowing clinical decline, there is an essential need for biomarker trials that will indicate whether a candidate disease-modifying therapeutic agent is actually altering the underlying degenerative process. A number of in-vivo neuroimaging techniques, which can reliably and noninvasively assess aspects of neuroanatomy, chemistry, physiology, and pathology, hold promise as biomarkers. These neuroimaging measures appear to relate closely to neuropathological and clinical data such as rate of cognitive decline and risk of future decline. As this work has matured, it has become clear that neuroimaging measures may serve a variety of potential roles in clinical trials of candidate neurotherapeutic agents for Alzheimer's disease, depending in part on the question of interest and phase of drug development.
The highly successful National Institute on Aging (NIA)-funded Alzheimer's Disease Neuroimaging Initiative (ADNI) program was established to increase knowledge of the mechanisms of Alzheimer's disease through the use of neuroimaging -thereby informing the development of treatment strategies aimed at slowing down or preventing neuronal death. ADNI has been instrumental in helping to identify clinical, neuroimaging, and biomarker outcome measures and longitudinal changes and the prediction of disease transitions. In particular, this has included neurodegeneration: the clinically and pathologically heterogeneous disease entity associated with slowly progressive neuronal loss in different anatomical and functional systems of the brain. Owing to increasing knowledge about the mechanisms leading to neurodegeneration as a result of ADNI, the development of treatments able to modify the neurodegenerative process will be easier. Although more research is clearly needed to determine the continued value of newer neuroimaging modalities, that is, diffusion, perfusion, and fMRI and magnetic resonance spectroscopy (MRS), for clinical trials with neuroprotective drugs, the ADNI project can be considered to have been a highly successful first step in large-scale neuroimaging and the sharing of that information with a larger community studying the efficacy of leading-edge treatment.
Additionally, researchers at NIA-funded Alzheimer's Disease Research Centers (ADRC) have worked to translate research advances into improved diagnosis and care for Alzheimer's disease patients while, at the same time, focusing on the program's long-term goalfinding a way to cure and possibly prevent Alzheimer's disease. Although each center has its own unique area of emphasis, a common goal of the Alzheimer's Disease Centers (ADCs) is to enhance research on Alzheimer's disease by providing a network for sharing new ideas as well as research results. Collaborative studies draw upon the expertise of scientists from many different disciplines. Some ADCs have satellite facilities, which offer diagnostic and treatment services and research opportunities in underserved, rural, and minority communities. The National Alzheimer's Coordinating Center at the University of Washington in Seattle, Washington coordinates data collection and fosters collaborative research among the ADCs. Additionally, the National Cell Repository for Alzheimer's Disease maintains a database of family histories and medical records and provides genetic researchers with cell lines and/or DNA samples. Several of the ADRCs also conduct neuroimaging investigations, but these data may not necessarily be widely available to researchers outside of each individual center. [32] . In particular, statistical analyses suggested that a mixed-effects model employing site as a random effect best fits the data, accounting for site-specific effects while taking advantage of expected comparability of age-related effects. In combining samples from three research sites, significant age-related decline of hippocampal volume and rightdominant hippocampal asymmetry were detected in healthy elderly controls. These findings support the feasibility of combining legacy as well as new data from across multiple sites toward investigating novel scientific questions.
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Fetal alcohol spectrum disorder
A recent neuroimaging thrust has been added to the Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD). One of the driving goals of the entire CIFASD has been to determine whether innovative techniques can be used to identify brain alterations, neurobehavioral deficits and facial characteristics and relationships between these variables to help define prenatal alcohol spectrum disorders [fetal alcohol spectrum disorder (FASD)]. To help address this, brain mapping using high-resolution structural MRI and fMRI collected cross-sectionally and longitudinally from 80 FASD children was evaluated across three distributed, multicultural data collection sites (San Diego, Los Angeles, and Cape Town). Their proposed longitudinal project seeks to highlight how an integrated approach relating neurobehavioral, functional and structural brain imaging data, and measures of facial (dys)morphology might yield important new insights on the complex nature of brain-behavior interactions and how they are altered by prenatal exposure to alcohol. Ultimately, this project, armed with neuroimaging outcomes, will enhance the capability for definitive FASD diagnoses that, in turn, will help clinicians manage and treat neurobehavioral deficits and associated secondary disabilities in FASD children.
Pediatric brain tumor
The Pediatric Brain Tumor Consortium (PBTC) was formed by the National Cancer Institute (NCI) in 1999 to improve the treatment of primary brain tumors in children. The primary objective of PBTC has been to rapidly conduct novel phase I and II clinical evaluations of new therapeutic drugs, new biological therapies, treatment delivery technologies, and radiation treatment strategies in children from infancy to 21 years of age with primary central nervous system (CNS) tumors. They develop and coordinate innovative neuroimaging techniques and their use in early diagnosis of pediatric brain cancer [30] , with resulting neuroimaging research being used to evaluate new treatment response criteria and the use of neuroimaging methods to understand regional brain effects [31, 33] .
Although this is not an exhaustive list of ongoing multisite efforts, it represents several examples of where neuroimaging has become a necessary and valuable part of collaborative research programs in the United States. It might not be surprising that the successes of these and other programs have been replicated in countries around the world [34, 35 ] , with interest rising in international collaborative efforts toward mapping the brain and its disorders [36 ,37] .
Future needs
Throughout the coming decade of human brain imaging research, given the trends toward collaborative effort across multiple institutions, we can expect to see still more multisite trials focused on particular neurological diseases and disorders. One such disease domain that is particularly poised for a multicenter collaboration is that of HIV and AIDS. In August 2008, the Centers for Disease Control (CDC) published the first national HIV incidence of new HIV infection estimates using new technology and methodology that more directly measures the number of new HIV infections in the United States [38] . Their new analyses showed that in 2006, an estimated 56 300 new HIV infections occurreda number that is considerably higher than the previous estimate of 40 000 annual new infections. However, though considerable progress has been made toward understanding the clinical response to various drugs designed to treat HIV/AIDS [39] , the examination of the long-term effects of the virus in the brain and its resistance to drugs via brain mapping technologies has only recently begun [40, 41] . Whereas multicenter efforts have focused on MRS neuroimaging in HIV/AIDS [42] , a more broadly based effort employing fMRI of cognitive functional changes, structural imaging of altered cortical thickness and other parameters, MRS, arterial spin labeling (ASL), as well as white matter imaging is sorely needed for assessing the effects of HIV on brain morphometry and function as well as the efficacy of extant and emerging HIV therapies.
Although the potential for clinical and treatment understanding is enhanced in multisite neuroimaging, considerable attention must be afforded to how such data might be efficiently organized, processed, and, firstly, made available to researchers at participating centers and then openly as a resource from which the entire neurological community might draw. The Laboratory of Neuro Imaging (LONI) has, for many years [43] , been at the forefront of providing the computational resources specifically tailored to support multicenter efforts [25, 44] , providing a large-scale Image Data Archive (IDA) for use in the secure databasing of clinical research neuroimaging data [45] , with long-term storage capabilities for petabyte levels of imaging study data. Still with advances in neuroimaging data acquisition methods that obtain more data per unit time, thereby making data computation considerations more serious, careful attention must be given to large-scale distributed grid computing approaches [46] and their use in processing ever larger quantities of data. The importance of neuroimaging informatics cannot be overstated in the context of multicenter collaborations and will be an active area of work that will help to maximize the success of any neurological research domain using neuroimaging data.
Evaluation of multisite outcomes
For many clinicians, interpreting the outcomes from multisite collaboratives can be challenging given the variety of neuroimaging terms being used, statistical methods being reported, and the sometimes lofty claims reported to justify the importance of the collaboration itself. Several factors are important to look for in evaluating the strengths of multisite trials and the outcomes from research collaboratives: identifying whether the study has published or is using openly available human imaging protocols; site-to-site quality assurance using standardized brain imaging phantoms; whether the sites involved are using the same or differing scanner platforms; performing a critical examination of whether the data were specifically obtained for the purposes of the study in question or if it is apparent that they were selected from a database for a secondary analysis; and clear and understandable experimental goals and their relationship with the multisite effort should be articulated in the study. Each of these considerations will put the work into the overall context of the multisite effort and guide the clinician in evaluating its quality, impact, and relevance to the patient level (Table 2) . Though multicenter efforts can frequently provide highly useful recommendations for the individual clinician, careful examinations of study quality and relevance remain important considerations before embarking on any new treatment programs based on their results.
Discussion
On a domestic or international scale, multisite neuroimaging efforts offer the promise for gaining insights into major brain disease and the characterization of normal structure and function. Multisite trials are an important element in the study of a disease or the process of evaluating an intervention. Linking together multiple sites facilitates the recruitment of large samples that yield high statistical power for both main analyses as well as secondary analyses of subgroups. Generalizability of results to the level of the population also is maximized. Because data come from multiple sites, investigators can explore how a treatment's effects vary across geographical diverse sites and how such variation relates to site characteristics, cultural and socio-economic factors. Such information can directly inform clinical decision-making at the level of the patient and guide the selection of treatment options. Multisite trials are costly, however, so the decisions that must be made, such as which population to study and the expense of gathering neuroimaging data, have particular importance for policy makers and site principal investigators.
Many authors have noted how neuroimaging technologies have emerged over the past 20 years and changed forever how we view the brain in health and disease across temporal and spatial dimensions [47, 48, 49] . But, clearly, neuroimaging as a research site-specific tool cannot begin to fully probe the subtleties of diseases that may vary culturally and geographically, whose effects may vary by age or sex, or that may result from a highly variable exposure to environmental or pharmacological mechanisms. Leveraging expertise and technologies from across distributed institutions, with inherent variation in technological infrastructural, theoretical, and clinical emphasis, is valuable toward building data resources of unprecedented size and scope. These may be mined and modeled to produce high-resolution maps of disease states in the brain and their responses to clinical intervention or treatment.
Coincident with developments in brain imaging technology and analysis approaches, the advantages for multisite neuroimaging endeavors have resulted in a steadily increasing number of multisite efforts in neurology and the brain sciences. Moving forward, we expect multisite efforts to form a mainstay of major scientific exploration of the normal and diseased brain. 
Conclusion
Multisite efforts toward mapping the human brain in health and disease will continue to grow over the next decade. These important efforts will link the intellectual talent and resources of leading research centers toward better understanding of primary brain diseases, cancer, as well as the normal brain in development and aging. With more data being obtained with a view toward greater spatiotemporal precision, the informatics of neuroimaging will be an important consideration. Finally, these efforts are imperative for guiding treatment recommendations for neurological disorders domestically and internationally as well as at the level of the individual patient. Multicenter collaborations can be expected to strengthen understanding of brain diseases that affect all walks of life, all ages, and all cultures. This helps to translate neuroimaging trial outcomes directly into clinical applications.
